Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).

Mulder MLM, Vriezekolk JE, den Broeder N, Mahler EAM, Helliwell PS, van den Hoogen FHJ, den Broeder AA, Wenink MH.

Trials. 2020 Feb 10;21(1):155. doi: 10.1186/s13063-020-4097-6.

2.

Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis.

Kersten BE, den Broeder N, van den Hoogen FHJ, Knaapen-Hans HAK, van den Ende CHM, Vonk MC.

Rheumatology (Oxford). 2020 Feb 10. pii: keaa047. doi: 10.1093/rheumatology/keaa047. [Epub ahead of print] No abstract available.

PMID:
32040189
3.

Exploring healthcare professionals' knowledge, attitudes and experiences of shared decision making in rheumatology.

Mathijssen EGE, van den Bemt BJF, Wielsma S, van den Hoogen FHJ, Vriezekolk JE.

RMD Open. 2020 Jan;6(1). pii: e001121. doi: 10.1136/rmdopen-2019-001121.

4.

Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.

Michielsens CAJ, Boers N, den Broeder N, Wenink MH, van der Maas A, Mahler EAM, Mulder MLM, van der Heijde D, van den Hoogen FHJ, Verhoef LM, den Broeder AA.

Trials. 2020 Jan 15;21(1):90. doi: 10.1186/s13063-019-4000-5.

5.

Comparison of physical activity among different subsets of patients with knee or hip osteoarthritis and the general population.

Pelle T, Claassen AAOM, Meessen JMTA, Peter WF, Vliet Vlieland TPM, Bevers K, van der Palen J, van den Hoogen FHJ, van den Ende CHM.

Rheumatol Int. 2020 Mar;40(3):383-392. doi: 10.1007/s00296-019-04507-1. Epub 2020 Jan 7.

PMID:
31912266
6.

An Electronic Health Tool to Prepare for the First Orthopedic Consultation: Use and Usability Study.

Claassen AAOM, Vliet Vlieland TPM, Busch VJJF, Schers HJ, van den Hoogen FHJ, van den Ende CHM.

JMIR Form Res. 2019 Nov 28;3(4):e13577. doi: 10.2196/13577.

7.

Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis.

Kersten BE, den Broeder N, van den Hoogen FHJ, Knaapen-Hans HAK, van den Ende CHM, Vonk MC.

Rheumatology (Oxford). 2019 Oct 19. pii: kez487. doi: 10.1093/rheumatology/kez487. [Epub ahead of print]

PMID:
31628802
8.

Interventions to support shared decision making for medication therapy in long term conditions: A systematic review.

Mathijssen EGE, van den Bemt BJF, van den Hoogen FHJ, Popa CD, Vriezekolk JE.

Patient Educ Couns. 2020 Feb;103(2):254-265. doi: 10.1016/j.pec.2019.08.034. Epub 2019 Aug 28. Review.

PMID:
31493959
9.

Development and evaluation of a tailored e-self-management intervention (dr. Bart app) for knee and/or hip osteoarthritis: study protocol.

Pelle T, Bevers K, van der Palen J, van den Hoogen FHJ, van den Ende CHM.

BMC Musculoskelet Disord. 2019 Aug 31;20(1):398. doi: 10.1186/s12891-019-2768-9.

10.

What moves the rheumatologist? Unravelling decision making in the referral of systemic sclerosis patients to health professionals: a qualitative study.

Stöcker JK, Cup EHC, Vonk MC, van den Hoogen FHJ, Nijhuis-van der Sanden MWG, Staal JB, van den Ende CHM.

Rheumatol Adv Pract. 2018 Aug 22;2(2):rky027. doi: 10.1093/rap/rky027. eCollection 2018.

11.

Implementing Psoriatic Arthritis Disease Activity Score-guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?

Mulder MLM, den Broeder AA, van Ginneken BTJ, Mahler EAM, van den Hoogen FHJ, Vriezekolk JE, Wenink MH.

Rheumatology (Oxford). 2019 Dec 1;58(12):2330-2331. doi: 10.1093/rheumatology/kez254. No abstract available.

PMID:
31230083
12.

Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van Herwaarden N, den Broeder AA.

Cochrane Database Syst Rev. 2019 May 24;5:CD010455. doi: 10.1002/14651858.CD010455.pub3.

PMID:
31125448
13.

Predictive value of ex-vivo drug-inhibited cytokine production for clinical response to biologic DMARD therapy in rheumatoid arthritis.

Tweehuysen L, den Broeder AA, Schraa K, Netea MG, van den Hoogen FHJ, Joosten LAB.

Clin Exp Rheumatol. 2019 May-Jun;37(3):367-372. Epub 2019 Feb 7.

PMID:
30767874
14.

Response to: 'Is it time to redefine the role of low-dose radiotherapy for benign disease?' by Montero et al.

Mahler EAM, Minten MJ, Leseman-Hoogenboom MM, Poortmans PMP, Leer JW, Boks SS, van den Hoogen FHJ, den Broeder AA, van den Ende CH.

Ann Rheum Dis. 2020 Mar;79(3):e35. doi: 10.1136/annrheumdis-2018-214896. Epub 2019 Feb 1. No abstract available.

PMID:
30709815
15.

Response to: 'Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis' by Wu et al.

Mahler EAM, Minten MJM, Leseman-Hoogenboom MM, Poortmans PMP, Leer JWH, Boks SS, van den Hoogen FHJ, den Broeder AA, van den Ende CH.

Ann Rheum Dis. 2020 Feb;79(2):e25. doi: 10.1136/annrheumdis-2018-214795. Epub 2019 Jan 4. No abstract available.

PMID:
30610062
16.

Exploring longitudinal associations of histologically assessed inflammation with symptoms and radiographic damage in knee osteoarthritis: combined results of three prospective cohort studies.

Minten MJM, Blom A, Snijders GF, Kloppenburg M, van den Hoogen FHJ, den Broeder AA, van der Kraan PM, van den Ende CHM.

Osteoarthritis Cartilage. 2019 Jan;27(1):71-79. doi: 10.1016/j.joca.2018.10.014. Epub 2018 Nov 16.

17.

Rheumatoid Arthritis Patients With Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity.

Arntz OJ, Pieters BCH, Thurlings RM, Wenink MH, van Lent PLEM, Koenders MI, van den Hoogen FHJ, van der Kraan PM, van de Loo FAJ.

Front Immunol. 2018 Oct 29;9:2388. doi: 10.3389/fimmu.2018.02388. eCollection 2018.

18.

Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial.

Mahler EAM, Minten MJ, Leseman-Hoogenboom MM, Poortmans PMP, Leer JWH, Boks SS, van den Hoogen FHJ, den Broeder AA, van den Ende CHM.

Ann Rheum Dis. 2019 Jan;78(1):83-90. doi: 10.1136/annrheumdis-2018-214104. Epub 2018 Oct 26.

PMID:
30366945
19.

Short-term clinical worsening is a clear predictor for worsening at 2 years in established knee and hip osteoarthritis.

Mahler EAM, den Broeder AA, den Broeder N, Bijlsma JWJ, Snijders GF, van den Hoogen FHJ, van den Ende CHM.

Clin Exp Rheumatol. 2019 May-Jun;37(3):414-421. Epub 2018 Sep 17.

PMID:
30299244
20.

Lack of beneficial effects of low-dose radiation therapy on hand osteoarthritis symptoms and inflammation: a randomised, blinded, sham-controlled trial.

Minten MJM, Leseman-Hoogenboom MM, Kloppenburg M, Kortekaas MC, Leer JW, Poortmans PMP, van den Hoogen FHJ, den Broeder AA, van den Ende CHM.

Osteoarthritis Cartilage. 2018 Oct;26(10):1283-1290. doi: 10.1016/j.joca.2018.06.010. Epub 2018 Jul 7.

21.

Three-year cost-effectiveness analysis of the DRESS study: protocolised tapering is key.

den Broeder N, Bouman CAM, Kievit W, van Herwaarden N, van den Hoogen FHJ, van Vollenhoven RF, Bijlsma HWJ, van der Maas A, den Broeder AA.

Ann Rheum Dis. 2019 Jan;78(1):141-142. doi: 10.1136/annrheumdis-2018-213547. Epub 2018 Aug 27. No abstract available.

PMID:
30150367
22.

Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial.

van den Hombergh WMT, Kersten BE, Knaapen-Hans HKA, Thurlings RM, van der Kraan PM, van den Hoogen FHJ, Fransen J, Vonk MC.

Trials. 2018 Aug 22;19(1):449. doi: 10.1186/s13063-018-2798-x.

23.

Most Important Frequently Asked Questions From Patients With Hip or Knee Osteoarthritis: A Best-Worst Scaling Exercise.

Claassen AAOM, Kremers-van de Hei KCALC, van den Hoogen FHJ, van der Laan WH, Rijnen WHC, Koëter S, Botman J, Busch VJJF, Schers HJ, van den Ende CHM.

Arthritis Care Res (Hoboken). 2019 Jul;71(7):885-892. doi: 10.1002/acr.23719. Epub 2019 May 21.

PMID:
30055092
24.

The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study.

Verhoef LM, Selten EMH, Vriezekolk JE, de Jong AJL, van den Hoogen FHJ, den Broeder AA, Hulscher ME.

Rheumatology (Oxford). 2018 Nov 1;57(11):1947-1955. doi: 10.1093/rheumatology/key205.

PMID:
30010899
25.

Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.

van den Hombergh WMT, Simons SO, Teesselink E, Knaapen-Hans HKA, van den Hoogen FHJ, Fransen J, Vonk MC.

Clin Rheumatol. 2018 Oct;37(10):2715-2722. doi: 10.1007/s10067-018-4171-6. Epub 2018 Jul 10.

26.

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis.

Tweehuysen L, den Broeder N, van Herwaarden N, Joosten LAB, van Lent PL, Vogl T, van den Hoogen FHJ, Thurlings RM, den Broeder AA.

RMD Open. 2018 Apr 9;4(1):e000654. doi: 10.1136/rmdopen-2018-000654. eCollection 2018.

27.

Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.

Tweehuysen L, Huiskes VJB, van den Bemt BJF, Vriezekolk JE, Teerenstra S, van den Hoogen FHJ, van den Ende CH, den Broeder AA.

Arthritis Rheumatol. 2018 Sep;70(9):1408-1418. doi: 10.1002/art.40516. Epub 2018 Aug 6.

28.

Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis.

Mathijssen EG, Vriezekolk JE, Eijsbouts AM, van den Hoogen FH, van den Bemt BJ.

Patient Prefer Adherence. 2018 Mar 7;12:349-358. doi: 10.2147/PPA.S152759. eCollection 2018.

29.

Ex vivo inhibited cytokine profiling may explain inferior treatment response to golimumab after adalimumab failure in rheumatoid arthritis.

Tweehuysen L, Schraa K, Netea MG, van den Hoogen FHJ, Joosten LAB, den Broeder AA.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):140-143. Epub 2017 Oct 18.

PMID:
29148425
30.

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab.

Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, den Broeder AA.

Arthritis Rheumatol. 2018 Jan;70(1):60-68. doi: 10.1002/art.40324. Epub 2017 Dec 7.

31.

Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial.

den Broeder AA, Verhoef LM, Fransen J, Thurlings R, van den Bemt BJF, Teerenstra S, Boers N, den Broeder N, van den Hoogen FHJ.

Trials. 2017 Aug 30;18(1):403. doi: 10.1186/s13063-017-2134-x.

32.

Patient Acceptable Symptom State in Knee Osteoarthritis Patients Succeeds Across Different Patient-reported Outcome Measures Assessing Physical Function, But Fails Across Other Dimensions and Rheumatic Diseases.

Mahler EAM, Boers N, Bijlsma JWJ, van den Hoogen FHJ, den Broeder AA, van den Ende CHM.

J Rheumatol. 2018 Jan;45(1):122-127. doi: 10.3899/jrheum.170181. Epub 2017 Aug 15.

PMID:
28811352
33.

Treatment Beliefs Underlying Intended Treatment Choices in Knee and Hip Osteoarthritis.

Selten EMH, Geenen R, Schers HJ, van den Hoogen FHJ, van der Meulen-Dilling RG, van der Laan WH, Nijhof MW, van den Ende CHM, Vriezekolk JE.

Int J Behav Med. 2018 Apr;25(2):198-206. doi: 10.1007/s12529-017-9671-2.

PMID:
28664420
34.

Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.

Bouman CA, van Herwaarden N, van den Hoogen FH, Fransen J, van Vollenhoven RF, Bijlsma JW, Maas AV, den Broeder AA.

Ann Rheum Dis. 2017 Oct;76(10):1716-1722. doi: 10.1136/annrheumdis-2017-211169. Epub 2017 Jun 12.

PMID:
28606961
35.

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?

Bouman CA, den Broeder AA, van der Maas A, van den Hoogen FH, Landewé RB, van Herwaarden N.

RMD Open. 2017 Mar 20;3(1):e000327. doi: 10.1136/rmdopen-2016-000327. eCollection 2017.

36.

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.

Bouman CAM, van der Maas A, van Herwaarden N, Sasso EH, van den Hoogen FHJ, den Broeder AA.

Rheumatology (Oxford). 2017 Jun 1;56(6):973-980. doi: 10.1093/rheumatology/kex003.

PMID:
28339738
37.

Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study.

Willems LM, Kwakkenbos L, Vonk MC, van den Hoogen FHJ, Vliet Vlieland TPM, van den Ende CHM.

Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 106(4):48-55. Epub 2017 Mar 8.

PMID:
28281452
38.

How should worsening in osteoarthritis be defined? Development and initial validation of preliminary criteria for clinical worsening in knee and hip osteoarthritis.

Mahler E, den Broeder AA, Woodworth TG, Busch V, van den Hoogen FH, Bijlsma J, van den Ende C.

Scand J Rheumatol. 2017 Sep;46(5):396-406. doi: 10.1080/03009742.2016.1235226. Epub 2017 Feb 7.

PMID:
28276959
39.

Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.

Tweehuysen L, van den Ende CH, Beeren FM, Been EM, van den Hoogen FH, den Broeder AA.

Arthritis Rheumatol. 2017 Feb;69(2):301-308. doi: 10.1002/art.39946. Review.

40.

An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation.

van den Hombergh WM, Carreira PE, Knaapen-Hans HK, van den Hoogen FH, Fransen J, Vonk MC.

Rheumatology (Oxford). 2016 Nov;55(11):2023-2032. Epub 2016 Aug 21.

PMID:
27550299
41.

High-Dose Intravenous Pulse Methotrexate in Patients With Eosinophilic Fasciitis.

Mertens JS, Zweers MC, Kievit W, Knaapen HK, Gerritsen M, Radstake TR, van den Hoogen FH, Creemers MC, de Jong EM.

JAMA Dermatol. 2016 Nov 1;152(11):1262-1265. doi: 10.1001/jamadermatol.2016.2873.

PMID:
27541801
42.

Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study.

Kranenburg P, van den Hombergh WM, Knaapen-Hans HK, van den Hoogen FH, Fransen J, Vonk MC.

Rheumatology (Oxford). 2016 Nov;55(11):2001-2008. Epub 2016 Aug 12.

PMID:
27520796
43.

Suppression of the inflammatory response by disease-inducible interleukin-10 gene therapy in a three-dimensional micromass model of the human synovial membrane.

Broeren MG, de Vries M, Bennink MB, Arntz OJ, van Lent PL, van der Kraan PM, van den Berg WB, van den Hoogen FH, Koenders MI, van de Loo FA.

Arthritis Res Ther. 2016 Aug 12;18:186. doi: 10.1186/s13075-016-1083-1.

44.

Milk-Derived Nanoparticle Fraction Promotes the Formation of Small Osteoclasts But Reduces Bone Resorption.

Oliveira MC, Di Ceglie I, Arntz OJ, van den Berg WB, van den Hoogen FH, Ferreira AV, van Lent PL, van de Loo FA.

J Cell Physiol. 2017 Jan;232(1):225-33. doi: 10.1002/jcp.25414. Epub 2016 Jun 2.

PMID:
27138291
45.

Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease.

Berende A, ter Hofstede HJ, Vos FJ, van Middendorp H, Vogelaar ML, Tromp M, van den Hoogen FH, Donders AR, Evers AW, Kullberg BJ.

N Engl J Med. 2016 Mar 31;374(13):1209-20. doi: 10.1056/NEJMoa1505425.

46.

Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.

Kievit W, van Herwaarden N, van den Hoogen FH, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, van der Maas A, den Broeder AA.

Ann Rheum Dis. 2016 Nov;75(11):1939-1944. doi: 10.1136/annrheumdis-2015-208317. Epub 2016 Jan 13.

PMID:
26764260
47.

Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.

van Herwaarden N, Bouman CA, van der Maas A, van Vollenhoven RF, Bijlsma JW, van den Hoogen FH, den Broeder AA, van den Bemt BJ.

Ann Rheum Dis. 2015 Dec;74(12):2260-1. doi: 10.1136/annrheumdis-2015-207814. Epub 2015 Sep 4. No abstract available.

PMID:
26342093
48.

(Bi)Weekly folic acid supplementation might be inferior to a daily folic acid dosing schedule in the prevention of methotrexate-related toxicity in patients with rheumatoid arthritis.

van den Bemt BJ, den Broeder AA, Van der Burgt M, Fransen J, van Ede AE, van den Hoogen FH.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5):767-8. Epub 2015 Aug 27. No abstract available.

PMID:
26316162
49.

Cost-Utility and Cost-Effectiveness Analyses of Face-to-Face Versus Telephone-Based Nonpharmacologic Multidisciplinary Treatments for Patients With Generalized Osteoarthritis.

Cuperus N, van den Hout WB, Hoogeboom TJ, van den Hoogen FH, Vliet Vlieland TP, van den Ende CH.

Arthritis Care Res (Hoboken). 2016 Apr;68(4):502-10. doi: 10.1002/acr.22709.

50.

Citrulline is an Essential Constituent of Antigenic Determinants Recognized by Rheumatoid Arthritis-specific Autoantibodies. 1998.

Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ.

J Immunol. 2015 Jul 1;195(1):8-16. No abstract available.

Supplemental Content

Loading ...
Support Center